EUVIMEDEUVIMED entdecken
Crossref

Single‐Dose, Long‐Acting Injectable Buprenorphine for Opioid Withdrawal Treatment

Jeffrey S Kruk iD, Judith L Fraser, Prasun Datta, Karen A Fisher

Drug and Alcohol Review · 2026

DOI: 10.1111/dar.70070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Alcohol Review, 2026. Verfasst von Jeffrey S Kruk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Addiction Medicine, Nepean Hospital, Kingswood, Australia. Hauptthemen laut MEDLINE: Buprenorphine, Substance Withdrawal Syndrome, Opioid-Related Disorders, Opiate Substitution Treatment. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long‐acting, injectable buprenorphine (LAIB) is a recently introduced opioid agonist treatment (OAT) for opioid dependence in Australia. Little research has been performed for its role in opioid withdrawal management.

Methods

A retrospective analysis of hospital patient records was conducted for five patients who received a single dose of LAIB as part of an inpatient or outpatient opioid withdrawal management program. Patients analysed had tried and failed conventional opioid withdrawal management and were unwilling to commence or continue an OAT program.

Results

Patient demographics including types of opioid use and inpatient lengths of stay are reported. Patient withdrawal symptoms before treatment and during follow‐up periods are also described. Overall, most patients were satisfied with a single dose of LAIB to adequately control withdrawal symptoms in the community. Discussion and Conclusions Given the stability of OAT patients on LAIB, it was inferred that some patients may do well in opioid withdrawal management using LAIB, should other conventional treatments not succeed. This was based on previous pharmacokinetic data and modelling by others which would allow for a slow, in vivo wean of the drug rather than discrete, daily dose reductions. For patients, this could reduce potential withdrawal symptoms and shorten admission lengths in hospital withdrawal management wards. Further research is needed to verify these results, but these preliminary data are encouraging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineSubstance Withdrawal SyndromeOpioid-Related DisordersOpiate Substitution TreatmentNarcotic AntagonistsHumansRetrospective StudiesAdultMaleFemaleDelayed-Action PreparationsMiddle AgedAustraliaInjections

Stichwörter der Autor:innen

buprenorphinedepot preparationopioid agonist treatmentopioid dependenceopioid use disorder

Substanzen

BuprenorphineNarcotic AntagonistsDelayed-Action Preparations

Autor:innen und Institutionen

  • Centre for Addiction Medicine, Nepean Hospital, Kingswood, Australia.

ORCID-Profile: Jeffrey S Kruk

Zitieren

APA

Kruk, J. S., Fraser, J. L., Datta, P., & Fisher, K. A. (2026). Single‐Dose, Long‐Acting Injectable Buprenorphine for Opioid Withdrawal Treatment. Drug and Alcohol Review. https://doi.org/10.1111/dar.70070

Vancouver

Kruk JS, Fraser JL, Datta P, Fisher KA. Single‐Dose, Long‐Acting Injectable Buprenorphine for Opioid Withdrawal Treatment. Drug and Alcohol Review. 2026. doi:10.1111/dar.70070

BibTeX
@article{Kruk2026,
  author = {Kruk, Jeffrey S and Fraser, Judith L and Datta, Prasun and Fisher, Karen A},
  title = {Single‐Dose, Long‐Acting Injectable Buprenorphine for Opioid Withdrawal Treatment},
  journal = {Drug and Alcohol Review},
  year = {2026},
  doi = {10.1111/dar.70070}
}
Kostenlos starten →